Baner

Programme


Download the programme in PDF
Thursday, 9 May 2019
16.00–17.00
Satellite session — EGIS

  • Theraphy of cardiovascular diseases  —  what's new?

prof. dr hab. n. med. Krzysztof Narkiewicz

  • Uric acid and cardiometabolic risk — historical and epidemiological perspective.

prof. Claudio Borghi

  • Hyperuricemia  —  the evolution of significance in the guidelines for the treatment of hypertension

prof. dr hab. n. med. Andrzej Tykarski

    17.00–17.15Welcome addresses
    17.15–19.15
    Opening lectures

    Chairpersons: Konstantinos Tsioufis (Greece), Stephane Laurent (France), Krzysztof Narkiewicz (Poland)

    1. The 2018 European Hypertension Guidelines — 2019 perspective
        Giuseppe Mancia (Italy)

    2. Hot topics in hypertension management
        Konstantinos Tsioufis (Greece)

    3. Precision Medicine — current status and future perspectives
        Anna Dominiczak (UK)

      Friday, 10 May 2019
      09.00–10.30
      Session I: Novel mechanisms and therapies

      Chairpersons: SigneAlliksoo (Estonia), Lyudmila Korostovtseva (Russia), Manuel de Carvalho Rodrigues (Portugal)

      1. Clinical utility of genetics and cardiometabolic biomarkers
          Olle Melander (Sweden)

      2. Novel concepts in vascular ageing — 2019 update
          Patrick Lacolley, Stephane Laurent (France)

      3. Recent evidences on the effect of urate-lowering treatment in patients at risk of cardiovascular diseases
         Claudio Borghi (Italy)

        10.30–11.00Poster viewing and coffee break
        11.00–13.00
        Session II: Progress in diagnostics

        Chairpersons: Teemu Niiranen (Finland), Yuri Sirenko (Ukraine), Thomas Weber (Austria)

        1. Subclinical target organ damage in hypertension — 2019 update
            Enrico Agabiti Rosei (Italy)

        2. A view to understand the microvasculature
            Roland Schmieder (Germany)

        3. The impact of different antihypertensive drugs on capillary network
            Sekib Sokolovic (Bosnia and Herzegovina)

        4. Comparison of conventional office BP and automated unattended BP measurement in population screening
            Renata Cifkova (Czech Republic)

        5. Role of home and ambulatory BP monitoring in the light of the recent US and European Guidelines
            Gianfranco Parati (Italy)

          13.00–14.00Lunch
          14.00–15.30
          Session III: Progress in management — part 1

          Chairpersons: Csaba Farsang (Hungary), Andrzej Januszewicz (Poland), Bruno Watschinger (Austria)

          1. Anticancer treatment, hypertension and cardiovascular complications
              Michel Azizi (France)

          2. Hypertension in patients after organ transplantation
              Marcin Adamczak (Poland)

          3. The international consensus on Fibromuscular Dysplasia: highlights and practical implementation
              Alexandre Persu (Belgium)

          4. Primary aldosteronism — 2019 update
              Jiri Widimsky Jr (Prague, Czech Republic)

            15.30–16.00Coffee break
            16.00–18.00
            Session IV: Progress in management — part 2

            Chairpersons: Zoltan Jarai (Hungary), Sabine Perl (Austria), Victor Snezhitsky (Belarus)

            1. Incident heart failure should not be included in the primary endpoint in open (not blinded) outcome trials in high risk hypertension
                Sverre E. Kjeldsen (Norway)

            2. Malignant hypertension: is it a complement disease?
                Marius Miglinas (Lithuania)

            3. Masked hypertension
                Karlis Trusinskis (Latvia)

            4. Do antihypertensive drugs induce cancer?
                Michel Burnier (Switzerland)

              Saturday, 11 May 2019
              09.00–10.30
              Topical Workshop: Joint ESH research projects — part 1

              Chairpersons: Tine de Baker (Belgium), Slavomira Filipova (Slovakia),Yoto Yotov (Bulgaria)

              1. ESH-BP Control Study
                  Bojan Jelaković (Croatia)

              2. ESH Atrial Fibrillation Research Project
                  Enrico Agabiti Rosei (Italy), Bojan Jelaković (Croatia)

                  Atrial fibrillation in hypertension — Slovak data
                  Slavomira Filipova (Slovakia)

              3. Multicentre study on the management of acute hypertensive events
                  Konstantinos Tsioufis (Greece)

                10.30–11.00Coffee break
                11.00–12.30
                Topical Workshop: Joint ESH research projects — part 2

                Chairpersons: Bojan Jelaković (Croatia), Vladislav Podpalov (Belarus), Anna Rekhviashvilli (Georgia)

                1. MASTER study
                    Gianfranco Parati (Italy)

                2. ESH Registry on Fibromuscular Dysplasia
                    The European Fibromuscular Dysplasia Initiative — current status, results and next steps
                    Alexandre Persu (Belgium)

                3. The ARCADIA-Pol Study — present status, results and future
                    Ewa Warchoł-Celińska (Poland), Andrzej Januszewicz (Poland)

                    Other projects

                  12.30–13.00Discussion
                  Thursday, 9 May 2019
                  16.00–17.00
                  Satellite session — EGIS

                  • Theraphy of cardiovascular diseases  —  what's new?

                  prof. dr hab. n. med. Krzysztof Narkiewicz

                  • Uric acid and cardiometabolic risk — historical and epidemiological perspective.

                  prof. Claudio Borghi

                  • Hyperuricemia  —  the evolution of significance in the guidelines for the treatment of hypertension

                  prof. dr hab. n. med. Andrzej Tykarski

                    17.00–17.15
                    Welcome addresses
                    17.15–19.15
                    Opening lectures

                    Chairpersons: Konstantinos Tsioufis (Greece), Stephane Laurent (France), Krzysztof Narkiewicz (Poland)

                    1. The 2018 European Hypertension Guidelines — 2019 perspective
                        Giuseppe Mancia (Italy)

                    2. Hot topics in hypertension management
                        Konstantinos Tsioufis (Greece)

                    3. Precision Medicine — current status and future perspectives
                        Anna Dominiczak (UK)

                      Friday, 10 May 2019
                      09.00–10.30
                      Session I: Novel mechanisms and therapies

                      Chairpersons: SigneAlliksoo (Estonia), Lyudmila Korostovtseva (Russia), Manuel de Carvalho Rodrigues (Portugal)

                      1. Clinical utility of genetics and cardiometabolic biomarkers
                          Olle Melander (Sweden)

                      2. Novel concepts in vascular ageing — 2019 update
                          Patrick Lacolley, Stephane Laurent (France)

                      3. Recent evidences on the effect of urate-lowering treatment in patients at risk of cardiovascular diseases
                         Claudio Borghi (Italy)

                        10.30–11.00
                        Poster viewing and coffee break
                        11.00–13.00
                        Session II: Progress in diagnostics

                        Chairpersons: Teemu Niiranen (Finland), Yuri Sirenko (Ukraine), Thomas Weber (Austria)

                        1. Subclinical target organ damage in hypertension — 2019 update
                            Enrico Agabiti Rosei (Italy)

                        2. A view to understand the microvasculature
                            Roland Schmieder (Germany)

                        3. The impact of different antihypertensive drugs on capillary network
                            Sekib Sokolovic (Bosnia and Herzegovina)

                        4. Comparison of conventional office BP and automated unattended BP measurement in population screening
                            Renata Cifkova (Czech Republic)

                        5. Role of home and ambulatory BP monitoring in the light of the recent US and European Guidelines
                            Gianfranco Parati (Italy)

                          13.00–14.00
                          Lunch
                          14.00–15.30
                          Session III: Progress in management — part 1

                          Chairpersons: Csaba Farsang (Hungary), Andrzej Januszewicz (Poland), Bruno Watschinger (Austria)

                          1. Anticancer treatment, hypertension and cardiovascular complications
                              Michel Azizi (France)

                          2. Hypertension in patients after organ transplantation
                              Marcin Adamczak (Poland)

                          3. The international consensus on Fibromuscular Dysplasia: highlights and practical implementation
                              Alexandre Persu (Belgium)

                          4. Primary aldosteronism — 2019 update
                              Jiri Widimsky Jr (Prague, Czech Republic)

                            15.30–16.00
                            Coffee break
                            16.00–18.00
                            Session IV: Progress in management — part 2

                            Chairpersons: Zoltan Jarai (Hungary), Sabine Perl (Austria), Victor Snezhitsky (Belarus)

                            1. Incident heart failure should not be included in the primary endpoint in open (not blinded) outcome trials in high risk hypertension
                                Sverre E. Kjeldsen (Norway)

                            2. Malignant hypertension: is it a complement disease?
                                Marius Miglinas (Lithuania)

                            3. Masked hypertension
                                Karlis Trusinskis (Latvia)

                            4. Do antihypertensive drugs induce cancer?
                                Michel Burnier (Switzerland)

                              Saturday, 11 May 2019
                              09.00–10.30
                              Topical Workshop: Joint ESH research projects — part 1

                              Chairpersons: Tine de Baker (Belgium), Slavomira Filipova (Slovakia),Yoto Yotov (Bulgaria)

                              1. ESH-BP Control Study
                                  Bojan Jelaković (Croatia)

                              2. ESH Atrial Fibrillation Research Project
                                  Enrico Agabiti Rosei (Italy), Bojan Jelaković (Croatia)

                                  Atrial fibrillation in hypertension — Slovak data
                                  Slavomira Filipova (Slovakia)

                              3. Multicentre study on the management of acute hypertensive events
                                  Konstantinos Tsioufis (Greece)

                                10.30–11.00
                                Coffee break
                                11.00–12.30
                                Topical Workshop: Joint ESH research projects — part 2

                                Chairpersons: Bojan Jelaković (Croatia), Vladislav Podpalov (Belarus), Anna Rekhviashvilli (Georgia)

                                1. MASTER study
                                    Gianfranco Parati (Italy)

                                2. ESH Registry on Fibromuscular Dysplasia
                                    The European Fibromuscular Dysplasia Initiative — current status, results and next steps
                                    Alexandre Persu (Belgium)

                                3. The ARCADIA-Pol Study — present status, results and future
                                    Ewa Warchoł-Celińska (Poland), Andrzej Januszewicz (Poland)

                                    Other projects

                                  12.30–13.00
                                  Discussion

                                  Organizator:

                                  Via Medica

                                  Patronat medialny:

                                  Via Medica

                                  Partner:

                                  Via Medica

                                  Strony konferencji Grupy Via Medica wykorzystują pliki cookies. Opcje dotyczące cookies można zmienić w ustawieniach przeglądarki internetowej.
                                  Korzystanie z niniejszej strony bez zmiany ustawień dotyczących cookies oznacza, że będą one zapisane w pamięci komputera. Czym są i do czego służą pliki cookie możesz dowiedzieć się na stronie www.wszystkoociasteczkach.pl